Review upcoming clinical trials with data readouts expected in the first half of 2026, providing updates relevant to ongoing research and clinical practice in neurology. The ADEPT-2 study assesses xanomeline/trospium for psychosis in Alzheimer's, potentially introducing a new class of therapies targeting muscarinic receptor agonism. The ELEVATE-PD trial examines IPX203 for Parkinson's, focusing on real-world efficacy and safety in patients with motor complications. REMODEL studies compare remibrutinib and teriflunomide in relapsing multiple sclerosis, with primary endpoints including annualized relapse rate and disability progression.SHOW MORE · Review upcoming clinical trials with data readouts expected in the first half of 2026, providing updates relevant to ongoing research and clinical practice in neurology. As the field of neurology advances, the early months of 2026 are anticipated to bring important clinical trial readouts that may influence research and care across multiple neurological conditions. These studies span a broad spectrum of disorders and aim to clarify disease mechanisms while evaluating emerging therapeutic approaches. Ranging from novel gene-based strategies to new pharmacologic interventions, the results may inform future treatment paradigms and clinical decision-making. At baseline, patients had a Clinical Dementia Rating-Sum of Boxes (CDR-SB) mean score, the primary end point, of 3.45 (± 1.70). On other secondary outcomes, such as Alzheimer’s Disease Assessment Scale – Cognitive Subscale, 13-item (ADAS-Cog13), patients had a baseline score of 27.75 (± 8.02). Recently, the FDA accepted an updated protocol for Annovis Bio’s · pivotal phase 3 AD study (NCT06709014) testing the therapeutic potential of its investigational agent buntanetap, an orally available small molecule, in AD. The study is designed to evaluate the primary end point of change in the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions score and the key secondary endpoint of Clinical Global Impression-Severity, with additional assessments on safety and tolerability compared with placebo. In the trial, participants aged 55 to 90 years with possible or probable AD disease will be randomly assigned to either an oral capsule of xanomeline/trospium or an oral capsule of placebo.4 Xanomeline/trospium, which is currently approved for schizophrenia in adults, has the potential to be the first treatment in a new class of pharmacologic therapies targeting agitation and psychosis based on muscarinic receptor agonism.5 Additional study results from the ADEPT program in psychosis associated with AD, including ADEPT-2, ADEPT-1 and ADEPT-4, are expected to be read out by the end of 2026.

Original title: “Key Neurology Trial Readouts to Watch in Early 2026 | NeurologyLive - Clinical Neurology News and Neurology Expert Insights”